Postherpetic neuralgia (PHN) has served—and continues to serve—as a gateway indication into the lucrative neuropathic pain (NP) therapy market. Drugs such as Pfizer’s Lyrica (pregabalin), gabapentin (Pfizer’s Neurontin, generics), and the 5% lidocaine patch (Endo/Grünenthal’s Lidoderm/Versatis, generics) all capitalized on their approvals for PHN in the United States and Europe to achieve wider commercial success in the treatment of other forms of NP, such as neuropathic back pain and postsurgical/post-trauma NP. Despite the availability of multiple generic analgesics and well-established treatments for PHN, the substantial percentage of patients refractory to treatment, the high rate of polypharmacy, and the large unmet need associated with pain treatment make PHN—and NP overall—an area of commercial opportunity.

Table of contents

  • Neuropathic Pain - Unmet Need - Detailed Expanded Analysis Postherpetic Neuralgia
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in Postherpetic Neuralgia
        • Importance of Efficacy Attributes to Prescribing Decisions in Postherpetic Neuralgia — United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Postherpetic Neuralgia — Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Postherpetic Neuralgia — United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Postherpetic Neuralgia — Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Postherpetic Neuralgia — United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Postherpetic Neuralgia — Europe
        • Importance of Non-Clinical Factors to Prescribing Decisions in Postherpetic Neuralgia — United States
        • Importance of Non-Clinical Factors to Prescribing Decisions in Postherpetic Neuralgia— Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in Postherpetic Neuralgia — United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in Postherpetic Neuralgia — Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products for Postherpetic Neuralgia
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for Postherpetic Neuralgia — United States
        • Overall Performance of Key Therapies for Postherpetic Neuralgia — Europe
        • Relative Performance of Key Therapies for Postherpetic Neuralgia Across Select Efficacy Attributes — United States
        • Relative Performance of Key Therapies for Postherpetic Neuralgia Across Select Efficacy Attributes — Europe
        • Relative Performance of Key Therapies for Postherpetic Neuralgia Across Select Safety and Tolerability Attributes — United States
        • Relative Performance of Key Therapies for Postherpetic Neuralgia Across Select Safety and Tolerability Attributes — Europe
        • Relative Performance of Key Therapies for Postherpetic Neuralgia Across Select Convenience of Administration Attributes — United States
        • Relative Performance of Key Therapies for Postherpetic Neuralgia Across Select Convenience of Administration Attributes — Europe
        • Relative Performance of Key Therapies for Postherpetic Neuralgia Across Select Non-Clinical Attributes — United States
        • Relative Performance of Key Therapies for Postherpetic Neuralgia Across Select Non-Clinical Attributes — Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Neurologists' Satisfaction with the Performance of Key Therapies for Postherpetic Neuralgia on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — United States
        • Surveyed Neurologists' Satisfaction with the Performance of Key Therapies for Postherpetic Neuralgia on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — Europe
      • Physician Rating of Unmet Need in Postherpetic Neuralgia
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Postherpetic Neuralgia — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Postherpetic Neuralgia — Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Postherpetic Neuralgia — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Postherpetic Neuralgia — Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Postherpetic Neuralgia — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Postherpetic Neuralgia — Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in Postherpetic Neuralgia — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in Postherpetic Neuralgia — Europe
      • Unmet Need in Postherpetic Neuralgia and Related Indications
        • Surveyed Neurologists' Ascribed Level of Unmet Need in Postherpetic Neuralgia and Related Indications — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need in Postherpetic Neuralgia and Related Indications — Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Postherpetic Neuralgia Market and Emerging Therapy Insights
        • Opportunity: A New Agent with Increased Efficacy Based on a Higher Patient Responder Rate
        • Opportunity: A New Agent with Greater Tolerability due to a Reduced Risk of Gastrointestinal Side Effects
        • Opportunity: A Novel Non-Oral Agent with Equivalent Efficacy
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
        • Assigned Prohibitions for the Conjoint Module
      • Attribute Importance and Part-Worth Utilities
        • Postherpetic Neuralgia Target Product Profile: Attribute Importance
        • Postherpetic Neuralgia Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Postherpetic Neuralgia Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Postherpetic Neuralgia Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Postherpetic Neuralgia Market Simulations: Target Product Profiles Included in Scenario 1
        • Postherpetic Neuralgia Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Postherpetic Neuralgia Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Postherpetic Neuralgia Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): Joyce Spadafora, ALM

Joyce is a business insights analyst in Decision Resources Group’s central nervous systems and ophthalmology division, where she provides expert insight into commercial aspects of drug development and market sizing across psychiatric and pain indications. She has worked extensively in DRG’s schizophrenia and chronic pain content.

Prior to joining DRG, Joyce spent several years in the biotech industry focused in research and development and in biotech consulting. Her project experience covered indications including psychiatry, pain, infectious diseases, respiratory, and ophthalmology. Beyond my therapeutic and industry knowledge, she holds a Masters in Extension Studies in Psychology from Harvard University and a B.S in Mechanical Engineering with Biology from the Massachusetts Institute of Technology.